These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 14730652)

  • 21. Pharmacologic approaches to correcting the basic defect in cystic fibrosis.
    Lukacs GL; Durie PR
    N Engl J Med; 2003 Oct; 349(15):1401-4. PubMed ID: 14534332
    [No Abstract]   [Full Text] [Related]  

  • 22. Pre-clinical and clinical endpoint assays for cystic fibrosis gene therapy.
    Griesenbach U; Boyd AC;
    J Cyst Fibros; 2005 May; 4(2):89-100. PubMed ID: 15914096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laboratory parameter profiles among patients with cystic fibrosis.
    Goss CH; Mayer-Hamblett N; Kronmal RA; Williams J; Ramsey BW
    J Cyst Fibros; 2007 Apr; 6(2):117-23. PubMed ID: 16829217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.
    Flume PA; O'Sullivan BP; Robinson KA; Goss CH; Mogayzel PJ; Willey-Courand DB; Bujan J; Finder J; Lester M; Quittell L; Rosenblatt R; Vender RL; Hazle L; Sabadosa K; Marshall B;
    Am J Respir Crit Care Med; 2007 Nov; 176(10):957-69. PubMed ID: 17761616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. rhDNase in cystic fibrosis.
    Conway SP; Littlewood JM
    Br J Hosp Med; 1997 Apr 16-May 6; 57(8):371-2. PubMed ID: 9274660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bacterial infections of the lungs in mucoviscidosis patients].
    Hogardt M; Heesemann J
    MMW Fortschr Med; 2005 Jan; 147(4):38-40. PubMed ID: 15745340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients.
    Westerman EM; Heijerman HG; Frijlink HW
    Expert Opin Drug Deliv; 2007 Mar; 4(2):91-4. PubMed ID: 17335406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland.
    Stelmach I; Korzeniewska A; Stelmach W
    Respiration; 2008; 75(2):178-81. PubMed ID: 17435382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developmental paradigm for early features of cystic fibrosis.
    Larson JE; Cohen JC
    Pediatr Pulmonol; 2005 Nov; 40(5):371-7. PubMed ID: 15830387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cystic fibrosis modifying genes].
    Knauer N; Ratjen F; Grasemann H
    Pneumologie; 2005 Jun; 59(6):395-404. PubMed ID: 15991075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
    Kerem E
    Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cystic fibrosis: ironing out the problem of infection?
    Reid DW; Anderson GJ; Lamont IL
    Am J Physiol Lung Cell Mol Physiol; 2008 Jul; 295(1):L23-4. PubMed ID: 18487353
    [No Abstract]   [Full Text] [Related]  

  • 34. Modifier genes in cystic fibrosis.
    Davies JC; Griesenbach U; Alton E
    Pediatr Pulmonol; 2005 May; 39(5):383-91. PubMed ID: 15765543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New drugs for cystic fibrosis.
    Wilschanski M; Kerem E
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1285-92. PubMed ID: 21745147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cystic fibrosis. Current indications for nebulized treatments: antibiotics and DNase].
    Sardet-Frismand A
    Rev Mal Respir; 1999 Jan; 16 Suppl 3():S131-2. PubMed ID: 10088286
    [No Abstract]   [Full Text] [Related]  

  • 37. Tobramycin is a suppressor of premature termination codons.
    Altamura N; Castaldo R; Finotti A; Breveglieri G; Salvatori F; Zuccato C; Gambari R; Panin GC; Borgatti M
    J Cyst Fibros; 2013 Dec; 12(6):806-11. PubMed ID: 23540394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
    Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R
    Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutrophilic inflammation as a major determinant in the progression of cystic fibrosis.
    Tirouvanziam R
    Drug News Perspect; 2006 Dec; 19(10):609-14. PubMed ID: 17299603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aquagenic wrinkling of the palms in an adult cystic fibrosis population.
    Tolland JP; Boyle J; Hall V; McKenna KE; Elborn JS
    Dermatology; 2010; 221(4):326-30. PubMed ID: 20881360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.